Although psychological distress was not improved, this tailored intervention addressed other potential gaps in care needs of patients with gynecologic cancers undergoing RT.
Observational study design and conflicts of interest prevent researchers from determining whether the FDA-mandated black box warning is warranted.
Different patterns of rheumatic symptoms were observed in patients with rheumatic irAEs.
Patients given prophylactic treatment were 94% less likely to require a first rescue treatment for rash and 74% less likely to require a second rescue treatment.
Researchers identified factors for increased risk of clinically significant fatigue among women who underwent surgery for gynecologic cancers.
Using a grading system for skin flare reactions increases potential for continuing administration of mogamulizumab despite the occurrence of this adverse effect.
Investigators aimed to compare the prevalence and likelihood of opioid use and misuse among cancer survivors and those without cancer.
This retrospective cohort analysis sought to determine the association between pRIA and radiation dose and response to treatment.
Researchers at UT MD Anderson Cancer Center in Houston present tools that support patient adherence to acalabrutinb in the setting of MCL.
A small study sought to determine if severe treatment-related skin rash could be treated without dose reduction or interruption in patients receiving imatinib for GIST.
